Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~AML project~* inclusion in studies of the DSIL or OSHO group for AML~* AML M3/M3v can be included only when in complete remission~* age 16 - 80 years~* written informed consent~Autologous project~* AMl and ALL patients in first or second remission~* low grade or high grade non hodgkin lymphoma or morbus hodgkin or multiple myeloma~* conditioning regime: TBI 8-12 Gy/Cy 120 or BEAM or BU/CY or Melphalan 140-200mg/m2 or a similarly intensive chemotherapy regime~* age 16 - 65 years~Exclusion Criteria:~AML project~* known refractoriness to platelet transfusion~* known major bleeding with thrombocytopenia when the reason for bleeding is still ongoing~* known plasmatic coagulation disorder~* patient unable to give informed consent~Autologous project~* known refractoriness to platelet transfusion~* known major bleeding with thrombocytopenia when the reason for bleeding is still ongoing~* known plasmatic coagulation disorder~* patient unable to give informed consent~* patients with pulmonal or cerebral lesions due to infection or neoplasm~* patients with al-amyloidosis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
- 2 (Type: ACTIVE_COMPARATOR): In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).